Results 1 to 10 of about 5,495 (171)

Efficacy and safety of fenfluramine in Dravet syndrome: The impact of patient clinical characteristics. [PDF]

Epilepsia Open
This graphical abstract provides an overview of the content from this post hoc analysis evaluating the efficacy and safety of fenfluramine in patients with Dravet syndrome stratified by age, number of previously attempted antiseizure medications, and SCN1A pathogenic variant status using data pooled from the three pivotal randomized controlled trials ...
Nabbout R, Sullivan J, Auvin S, Cross JH, Devinsky O, Gil-Nagel A, Guerrini R, Knupp KG, Perry MS, Sánchez-Carpintero R, Schoonjans AS, Scheffer IE, Specchio N, Strzelczyk A, Wheless J, Wirrell EC, Morita D, Healy P, Langlois M, Lothe A, Lagae L.   +20 more
europepmc   +3 more sources

Changes in effectiveness and safety in patients with Lennox-Gastaut syndrome transitioning from the fenfluramine randomized controlled trial to open-label extension study. [PDF]

Epilepsia Open
This graphical abstract provides an overview of the content from this post hoc analysis describing the trajectories of fenfluramine effectiveness and safety, along with dose changes over time, in patients with Lennox‐Gastaut syndrome. Abstract In the phase 3 randomized controlled trial (RCT; NCT03355209) of fenfluramine in Lennox–Gastaut syndrome (LGS),
Nabbout R, Devinsky O, Lagae L, Scheffer IE, Guerrini R, Sullivan J, Gil-Nagel A, Zuberi SM, Riney K, Healy P, Abraham J, Roper RZ, Langlois M, Lothe A, Knupp KG.   +14 more
europepmc   +2 more sources

Efficacy of stiripentol, fenfluramine, and their combination on clinical outcomes in Dravet syndrome: A preliminary report. [PDF]

Epilepsia Open
Abstract Objective Stiripentol and fenfluramine are approved treatments for Dravet syndrome (DS), but real‐world data comparing their effectiveness and combined use remain limited. Our study aims to explore associations between treatment with stiripentol, fenfluramine, and their combination and clinical outcomes in patients with DS.
Surdi P, Trivisano M, Mercier M, Pietrafusa N, De Dominicis A, Calabrese C, Cappelletti S, Specchio N.   +7 more
europepmc   +2 more sources

Pharmacovigilance study on old drugs repurposed for rare diseases across different indications: the case of fenfluramine [PDF]

Frontiers in Pharmacology
ObjectiveAs an old drug with a new application in rare diseases with epileptic symptoms, fenfluramine may have potential unrecognized adverse events.
Jiahong Zhong, Zhuomiao Lin, Junling Xue, Xihui Yu   +3 more
doaj   +2 more sources

Fenfluramine for seizures in Dravet syndrome and Lennox-Gastaut syndrome: Mechanisms, clinical evidence, safety, and practical integration [PDF]

Epilepsy & Behavior Reports
Developmental and epileptic encephalopathies such as Dravet syndrome and Lennox–Gastaut syndrome remain highly drug resistant and are associated with substantial neurodevelopmental, behavioral, and caregiver burdens.
József Janszky, József Janszky, Jr, Réka Horváth   +2 more
doaj   +2 more sources

Fenfluramine: An Uncommon Cause of False Positive Urine Drug Testing: A Case Report [PDF]

Annals of the Child Neurology Society
Background Fenfluramine is an antiseizure medication approved by the Food and Drug Administration for the treatment of Dravet syndrome in patients older than 2 years. Fenfluramine is an amphetamine derivative.
Maria Ghawji, Meagan Hainlen, Charuta Joshi   +2 more
doaj   +2 more sources

Safety of Drugs Used in Difficult-to-Treat Epileptic Syndromes: A Disproportionality Analysis Using the Eudravigilance Database [PDF]

Pharmaceuticals
Background/Objectives: Difficult-to-treat epileptic syndromes include conditions typically emerging in the first years of life and are characterized by a high rate of drug refractoriness. This study aimed to better define the safety profile of drugs used
Arianna Scala, Teresa Angela Trunfio, Chiara Pennisi, Giovanni Enrico Lombardo, Vincenzo Micale, Serena Di Martino, Giorgia Fiorenza, Adriana Carol Eleonora Graziano, Marilena Briglia, Fabio Allia, Giovanni Giurdanella, Roberta Malaguarnera, Rosalia Battaglia, Cecilia Gozzo, Fanny Erika Palumbo, Calogero Vetro, Giovanni Improta, Mario Damiano Toro, Filippo Drago, Giovanni Luca Romano, Lucia Gozzo   +20 more
doaj   +2 more sources

SUDEP and mortality in developmental and epileptic encephalopathies: A meta-analysis of randomized clinical trials and extension studies. [PDF]

Epilepsia
Abstract Objective Developmental and epileptic encephalopathies (DEEs) are associated with high premature mortality and increased risk of sudden unexpected death in epilepsy (SUDEP). However, epidemiological data remain limited, particularly for specific syndromes such as Dravet syndrome (DS), Lennox–Gastaut syndrome (LGS), and infantile epileptic ...
Moro P, Borioni MS, Mazzeo A, Cocchi E, Bonaventura CD, Cerulli Irelli E.   +5 more
europepmc   +2 more sources

Fenfluramine in SCN1A‐related GEFS+: A multicenter observational study on efficacy, EEG improvement, and tolerability [PDF]

Epilepsia Open
The SCN1A gene is implicated in a broad spectrum of epilepsy phenotypes, ranging from self‐limited genetic epilepsy with febrile seizures plus (GEFS+) to severe developmental and epileptic encephalopathies such as Dravet syndrome (DS). While fenfluramine
Giovanni B. Dell'Isola, Alice Muda, Lucio Giordano, Renzo Guerrini, Alessandra Boncristiano, Nicola Pietrafusa, Maria Polselli, Francesca Bisulli, Francesca Ragona, Antonella Riva, Pasquale Striano, Domenica Immacolata Battaglia, Federico Vigevano   +12 more
doaj   +2 more sources

Vagus nerve stimulation in KCNB1-related developmental and epileptic encephalopathy: A case of seizure reduction and review of literature [PDF]

Epilepsy & Behavior Reports
Developmental and epileptic encephalopathies (DEEs) are devastating syndromes characterized by early-onset, treatment-resistant seizures, and significant developmental delays.
Taichi Sayanagi, Kenzo Kosugi, Eri Ogawa, Toshiki Takenouchi, Mamiko Yamada, Kenjiro Kosaki, Ichiro Sugiyama, Masahiro Toda   +7 more
doaj   +2 more sources